HC Wainwright Has Positive Outlook of RNAZ FY2024 Earnings

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – HC Wainwright boosted their FY2024 earnings estimates for shares of TransCode Therapeutics in a report issued on Wednesday, December 18th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($4.76) for the year, up from their previous estimate of ($60.73). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($3.21) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.62) EPS.

TransCode Therapeutics Price Performance

Shares of NASDAQ RNAZ opened at $3.52 on Monday. TransCode Therapeutics has a twelve month low of $3.21 and a twelve month high of $264.00. The firm has a 50-day moving average of $365.27 and a two-hundred day moving average of $532.02.

Hedge Funds Weigh In On TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management increased its position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.